BACKGROUND: Hypomagnesemia (plasma magnesium (Mg2+) concentration <0.7 mmol/L) has been described in patients with type 2 diabetes. Polypharmacy is inevitable when treating a complex disease such as type 2 diabetes and could explain disturbances in the plasma Mg2+ concentration. In this study, we aimed to establish the extent of hypomagnesemia in a cohort of type 2 diabetes patients and to identify the determinants of plasma Mg2+ levels. METHODS: Patient data and samples of 395 type 2 diabetes patients were investigated. Plasma Mg2+ concentrations were measured using a spectrophotometric assay. Using Pearson correlation analyses, variables were correlated to plasma Mg2+ levels. After excluding confounding variables, all parameters correlating (P < 0.1) with plasma Mg2+ were included in a stepwise backward regression model. RESULTS: The mean plasma Mg2+ concentration in this cohort was 0.74 ± 0.10 mmol/L. In total, 121 patients (30.6%) suffered from hypomagnesemia. Both plasma triglyceride (r = -0.273, P < 0.001) and actual glucose levels (r = -0.231, P < 0.001) negatively correlated with the plasma Mg2+ concentration. Patients using metformin (n = 251, 62%), proton pump inhibitors (n = 179, 45%) or β-adrenergic receptor agonists (n = 31, 8%) displayed reduced plasma Mg2+ levels. Insulin use (n = 299, 76%) positively correlated with plasma Mg2+ levels. The model predicted (R2) 20% of all variance in the plasma Mg2+ concentration. CONCLUSIONS: Hypomagnesemia is highly prevalent in type 2 diabetes patients. Plasma triglycerides and glucose levels are major determinants of the plasma Mg2+ concentration, whereas only a minor part (<10%) of hypomagnesemia can be explained by drug intake, excluding polypharmacy as a major cause for hypomagnesemia in type 2 diabetes.
BACKGROUND:Hypomagnesemia (plasma magnesium (Mg2+) concentration <0.7 mmol/L) has been described in patients with type 2 diabetes. Polypharmacy is inevitable when treating a complex disease such as type 2 diabetes and could explain disturbances in the plasma Mg2+ concentration. In this study, we aimed to establish the extent of hypomagnesemia in a cohort of type 2 diabetespatients and to identify the determinants of plasma Mg2+ levels. METHODS:Patient data and samples of 395 type 2 diabetespatients were investigated. Plasma Mg2+ concentrations were measured using a spectrophotometric assay. Using Pearson correlation analyses, variables were correlated to plasma Mg2+ levels. After excluding confounding variables, all parameters correlating (P < 0.1) with plasma Mg2+ were included in a stepwise backward regression model. RESULTS: The mean plasma Mg2+ concentration in this cohort was 0.74 ± 0.10 mmol/L. In total, 121 patients (30.6%) suffered from hypomagnesemia. Both plasma triglyceride (r = -0.273, P < 0.001) and actual glucose levels (r = -0.231, P < 0.001) negatively correlated with the plasma Mg2+ concentration. Patients using metformin (n = 251, 62%), proton pump inhibitors (n = 179, 45%) or β-adrenergic receptor agonists (n = 31, 8%) displayed reduced plasma Mg2+ levels. Insulin use (n = 299, 76%) positively correlated with plasma Mg2+ levels. The model predicted (R2) 20% of all variance in the plasma Mg2+ concentration. CONCLUSIONS:Hypomagnesemia is highly prevalent in type 2 diabetespatients. Plasma triglycerides and glucose levels are major determinants of the plasma Mg2+ concentration, whereas only a minor part (<10%) of hypomagnesemia can be explained by drug intake, excluding polypharmacy as a major cause for hypomagnesemia in type 2 diabetes.
Authors: Peter R van Dijk; Joëlle C Schutten; Elias J Jeyarajah; Jenny E Kootstra-Ros; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: Diabetologia Date: 2019-06-27 Impact factor: 10.122
Authors: Mingzhu Nie; Manjot S Bal; Jie Liu; Zhufeng Yang; Carolina Rivera; Xue-Ru Wu; Joost G J Hoenderop; René J M Bindels; Denise K Marciano; Matthias T F Wolf Journal: J Biol Chem Date: 2018-08-23 Impact factor: 5.157
Authors: Silvia Ferrè; Xilong Li; Beverley Adams-Huet; Naim M Maalouf; Khashayar Sakhaee; Robert D Toto; Orson W Moe; Javier A Neyra Journal: J Investig Med Date: 2019-03-02 Impact factor: 2.895
Authors: Janina Vavanikunnel; Lilian Sewing; Maria Triantafyllidou; Anna Steighardt; Sandra Baumann; Andrea Egger; Leticia Grize; Barbara Felix; Marius Kraenzlin; Christoph Henzen; Christian Meier Journal: Calcif Tissue Int Date: 2022-10-03 Impact factor: 4.000
Authors: Tanguy Corre; Francisco J Arjona; Caroline Hayward; Sonia Youhanna; Jeroen H F de Baaij; Hendrica Belge; Nadine Nägele; Huguette Debaix; Maxime G Blanchard; Michela Traglia; Sarah E Harris; Sheila Ulivi; Rico Rueedi; David Lamparter; Aurélien Macé; Cinzia Sala; Stefania Lenarduzzi; Belen Ponte; Menno Pruijm; Daniel Ackermann; Georg Ehret; Daniela Baptista; Ozren Polasek; Igor Rudan; Toby W Hurd; Nicholas D Hastie; Veronique Vitart; Geràrd Waeber; Zoltán Kutalik; Sven Bergmann; Rosa Vargas-Poussou; Martin Konrad; Paolo Gasparini; Ian J Deary; John M Starr; Daniela Toniolo; Peter Vollenweider; Joost G J Hoenderop; René J M Bindels; Murielle Bochud; Olivier Devuyst Journal: J Am Soc Nephrol Date: 2017-11-01 Impact factor: 10.121
Authors: Katherine M Wang; JingWei Li; Vivek Bhalla; Meg J Jardine; Bruce Neal; Dick de Zeeuw; Greg Fulcher; Vlado Perkovic; Kenneth W Mahaffey; Tara I Chang Journal: Endocrinol Diabetes Metab Date: 2021-03-13